Belite Bio Statistics
Total Valuation
Belite Bio has a market cap or net worth of $1.11 billion. The enterprise value is $1.02 billion.
Market Cap | 1.11B |
Enterprise Value | 1.02B |
Important Dates
The next estimated earnings date is Saturday, May 11, 2024, before market open.
Earnings Date | May 11, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Belite Bio has 29.75 million shares outstanding.
Shares Outstanding | 29.75M |
Owned by Insiders (%) | 60.29% |
Owned by Institutions (%) | 0.81% |
Float | 11.21M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 12.26 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.76, with a Debt / Equity ratio of 0.01.
Current Ratio | 24.76 |
Quick Ratio | 24.50 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -1,263.92 |
Financial Efficiency
Return on equity (ROE) is -48.00% and return on invested capital (ROIC) is -34.68%.
Return on Equity (ROE) | -48.00% |
Return on Assets (ROA) | -45.50% |
Return on Capital (ROIC) | -34.68% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.58M |
Employee Count | 20 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Belite Bio has paid $9,000 in taxes.
Income Tax | 9,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +24.82% in the last 52 weeks.
Beta (1Y) | n/a |
52-Week Price Change | +24.82% |
50-Day Moving Average | 41.89 |
200-Day Moving Average | 36.68 |
Relative Strength Index (RSI) | 46.28 |
Average Volume (30 Days) | 50,166 |
Short Selling Information
Short Interest | 39,121 |
Short Previous Month | 59,470 |
Short % of Shares Out | 0.33% |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.76 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -31.67M |
Pretax Income | -31.62M |
Net Income | -31.63M |
EBITDA | -31.20M |
EBIT | -31.60M |
Earnings Per Share (EPS) | -$1.19 |
Balance Sheet
The company has $88.16 million in cash and $886,000 in debt, giving a net cash position of $87.27 million or $2.93 per share.
Cash & Cash Equivalents | 88.16M |
Total Debt | 886,000 |
Net Cash | 87.27M |
Net Cash Per Share | $2.93 |
Equity / Book Value | 90.43M |
Book Value Per Share | 3.04 |
Working Capital | 86.31M |
Cash Flow
In the last 12 months, operating cash flow was -$29.84 million and capital expenditures -$63,000, giving a free cash flow of -$29.90 million.
Operating Cash Flow | -29.84M |
Capital Expenditures | -63,000 |
Free Cash Flow | -29.90M |
FCF Per Share | -$1.12 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Belite Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -33.12% |
Shareholder Yield | -33.12% |
Earnings Yield | -2.85% |
FCF Yield | -2.70% |
Analyst Forecast
The average price target for Belite Bio is $48.80, which is 30.94% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $48.80 |
Price Target Difference | 30.94% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |